# US 2022/0031860 A1 · Antibodies modified for transglutaminase conjugation, conjugates thereof, and methods and uses

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0031860 A1
- Document ID: US20220031860A1
- Status: Published application
- Kind: A1
- Application number: 17/297,830
- Filed: 2019-12-10
- Published: 2022-02-03
- Earliest claimed: 2018-12-12
- Assignees: Bristol-Myers Squibb Company
- Applicants: Bristol-Myers Squibb Company
- Inventors: Pavel STROP; Chetana RAO-NAIK; Xiaodi DENG; Paul O. SHEPPARD; Sean Matthew WEST; Jason Michael HOGAN; Sayumi YAMAZOE
- Web page: https://patentgrep.com/patent/US20220031860A1

## CPC

- A61K 47/6803: {Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates}
- A61K 47/6851: {the antibody targeting a determinant of a tumour cell}
- A61K 47/6889: {Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment}
- C07K 16/30: from tumour cells
- C07K 2317/522: CH1 domain
- C07K 2317/524: CH2 domain
- C07K 2317/526: CH3 domain
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K 2319/00: Fusion polypeptide
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Antibodies are modified by replacing amino acids in the heavy chain CH1, CH2, or CH3 or light chain constant region with selected replacement glutamine-containing sequences to render them amenable to conjugation by the enzyme transglutaminase.

## Claims

### Claim 1

A full-length IgG antibody, having a modification selected from the group consisting of:
(i) replacement of the amino acids at EU 131 through 135 of a heavy chain with the amino acids of SEQ ID NO:7, SEQ ID NO:8, and SEQ ID NO: 9 or SEQ ID NO:10;
(ii) replacement of the amino acids at EU 160 through 164 of a heavy chain with the amino acids of SEQ ID NO:11, SEQ ID NO: 12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:16, or SEQ ID NO:17;
(iii) replacement of the amino acids at EU 175 through 177 of a heavy chain with the amino acids of SEQ ID NO:18, SEQ ID NO:19, or NO:20;
(iv) replacement of the amino acids at EU 190 through 196 of a heavy chain with the amino acids of SEQ ID NO:22, SEQ ID NO:23, or SEQ ID NO:24;
(v) replacement of the amino acids at EU 264 through 269 of a heavy chain with the amino acids of SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27 or SEQ NO:28;
(vi) replacement of the amino acids at EU 280 through 284 of a heavy chain with the amino acids of SEQ ID NO:29, SEQ ID NO:30, or SEQ ID NO:31;
(vii) replacement of the amino acids at EU 292 through 297 of a heavy chain with the amino acids of SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ Id NO:36, SEQ ID NO:37, SEQ ID NO: 38, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:45, SEQ ID NO:47, SEQ ID NO:100, SEQ ID NO:101, SEQ ID NO:102, or SEQ ID NO:103;
(viii) replacement of the amino acids at EU 314 through 319 of a heavy chain with the amino acids of SEQ ID NO:48, SEQ ID NO:49 or SEQ ID NO:50;
(ix) replacement of the amino acids at EU 330 through 331 of a heavy chain with the amino acids of SEQ ID NO:51, SEQ ID NO:52, or SEQ ID NO:53;
(x) replacement of the amino acids at EU 358 through 362 of a heavy chain with the amino acids of SEQ ID NO:54 or SEQ ID NO:55;
(xi) replacement of the amino acids at EU 384 through 402 of a heavy chain with the amino acids of SEQ ID NO:56, SEQ ID NO:57, SEQ ID NO:58, SEQ ID NO:59, SEQ ID NO:60, SEQ ID NO:61, SEQ ID NO:62, SEQ ID NO:63 or SEQ ID NO:64;
(xii) replacement of the amino acids at EU 414 through 419 of a heavy chain with the amino acids of SEQ ID NO:65, SEQ ID NO:66, SEQ ID NO:67, SEQ ID NO:68, or SEQ ID NO:69;
(xiii) replacement of the amino acids at EU 122 through 126 of a light chain with the amino acids of SEQ ID NO:70, SEQ ID NO:71, or SEQ ID NO:72;
(xiv) replacement of the amino acids at EU 152 through 155 of a light chain with the amino acids of SEQ ID NO:73, SEQ ID NO:74, or SEQ ID NO:75;
(xv) replacement of the amino acids at EU 167 through 170 of a light chain with the amino acids of SEQ ID NO:76, SEQ ID NO: 77, SEQ ID NO:78, SEQ ID NO: 79, SEQ ID NO:81, or SEQ ID NO:82;
(xvi) replacement of the amino acids at EU 182 through 190 of a light chain with the amino acids of SEQ ID NO:83, SEQ ID NO:84, SEQ ID NO:85, SEQ ID NO:86, or SEQ ID NO:87; and
(xvii) replacement of the amino acids at EU 199 through 204 of a light chain with the amino acids of SEQ ID NO:89, SEQ ID NO:90, SEQ ID NO:91, SEQ ID NO:92, SEQ ID NO:93, SEQ ID NO:94, SEQ ID NO:95, or SEQ ID NO:96.

### Claim 2 (depends on 1)

The antibody of claim 1, which is an IgG1 antibody.

### Claim 3 (depends on 2)

The antibody of claim 2, wherein the modification is in a heavy chain.

### Claim 4 (depends on 2)

The antibody of claim 2, wherein the modification is selected from the group consisting of:
(I) replacement of the amino acids at EU 131 through 135 of a heavy chain with the amino acids of SEQ ID NO:9 or SEQ ID NO:10;
(II) replacement of the amino acids at EU 175 through 177 of a heavy chain with the amino acids of SEQ ID NO:18;
(III) replacement of the amino acids at EU 190 through 196 of a heavy chain with the amino acids of SEQ ID NO:22;
(IV) replacement of the amino acids at EU 264 through 269 of a heavy chain with the amino acids of SEQ ID NO:27 or SEQ ID NO:28;
(V) replacement of the amino acids at EU 292 through 297 of a heavy chain with the amino acids of SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:45, SEQ ID NO:100, SEQ ID NO:101, SEQ ID NO:102, or SEQ ID NO:103;
(VI) replacement of the amino acids at EU 330 through 331 of a heavy chain with the amino acids of SEQ ID NO: 51, SEQ ID NO:52 or sEQ ID NO:53;
(VII) replacement of the amino acids at EU 384 through 402 of a heavy chain with the amino acids of SEQ ID NO:57, SEQ ID NO:58, or SEQ ID NO:63;
(VIII) replacement of the amino acids at EU 414 through 419 of a heavy chain with the amino acids of SEQ ID NO:66 or SEQ ID NO:68;
(IX) replacement of the amino acids at EU 152 through 155 of a light chain with the amino acids of SEQ ID NO:73 or SEQ ID NO:75;
(X) replacement of the amino acids at EU 167 through 170 of a light chain with the amino acids of SEQ ID NO: 78 or SEQ ID NO:82; and
(XI) replacement of the amino acids at EU 199 through 204 of a light chain with the amino acids of SEQ ID NO: 92, SEQ ID NO:93 or SEQ ID NO:94.

### Claim 5 (depends on 2)

The antibody of claim 2, wherein the modification is in a kappa light chain.

### Claim 6 (depends on 2)

The antibody of claim 2, wherein the replacement sequence comprises the tripeptide—VLQ-.

### Claim 7

A conjugate of the formula (IV)
wherein
Ab is a full length antibody having a replacement sequence selected from the group consisting of:
(i) replacement of the amino acids at EU 131 through 135 of a heavy chain with the amino acids of SEQ ID NO:7, SEQ ID NO:8, and SEQ ID NO: 9 or SEQ ID NO:10;
(ii) replacement of the amino acids at EU 160 through 164 of a heavy chain with the amino acids of SEQ ID NO:11, SEQ ID NO: 12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:16, or SEQ ID NO:17;
(iii) replacement of the amino acids at EU 175 through 177 of a heavy chain with the amino acids of SEQ ID NO:18, SEQ ID NO:19, or NO:20;
(iv) replacement of the amino acids at EU 190 through 196 of a heavy chain with the amino acids of SEQ ID NO:22, SEQ ID NO:23, or SEQ ID NO:24;
(v) replacement of the amino acids at EU 264 through 269 of a heavy chain with the amino acids of SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27 or SEQ NO:28;
(vi) replacement of the amino acids at EU 280 through 284 of a heavy chain with the amino acids of SEQ ID NO:29, SEQ ID NO:30, or SEQ ID NO:31;
(vii) replacement of the amino acids at EU 292 through 297 of a heavy chain with the amino acids of SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ Id NO:36, SEQ ID NO:37, SEQ ID NO: 38, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:45, SEQ ID NO:47, SEQ ID NO:100, SEQ ID NO:101, SEQ ID NO:102, or SEQ ID NO:103;
(viii) replacement of the amino acids at EU 314 through 319 of a heavy chain with the amino acids of SEQ ID NO:48, SEQ ID NO:49 or SEQ ID NO:50;
(ix) replacement of the amino acids at EU 330 through 331 of a heavy chain with the amino acids of SEQ ID NO:51, SEQ ID NO:52, or SEQ ID NO:53;
(x) replacement of the amino acids at EU 358 through 362 of a heavy chain with the amino acids of SEQ ID NO:54 or SEQ ID NO:55;
(xi) replacement of the amino acids at EU 384 through 402 of a heavy chain with the amino acids of SEQ ID NO:56, SEQ ID NO:57, SEQ ID NO:58, SEQ ID NO:59, SEQ ID NO:60, SEQ ID NO:61, SEQ ID NO:62, SEQ ID NO:63 or SEQ ID NO:64;
(xii) replacement of the amino acids at EU 414 through 419 of a heavy chain with the amino acids of SEQ ID NO:65, SEQ ID NO:66, SEQ ID NO:67, SEQ ID NO:68, or SEQ ID NO:69;
(xiii) replacement of the amino acids at EU 122 through 126 of a light chain with the amino acids of SEQ ID NO:70, SEQ ID NO:71, or SEQ ID NO:72;
(xiv) replacement of the amino acids at EU 152 through 155 of a light chain with the amino acids of SEQ ID NO:73, SEQ ID NO:74, or SEQ ID NO:75;
(xv) replacement of the amino acids at EU 167 through 170 of a light chain with the amino acids of SEQ ID NO:76, SEQ ID NO: 77, SEQ ID NO:78, SEQ ID NO: 79, SEQ ID NO:81, or SEQ ID NO:82;
(xvi) replacement of the amino acids at EU 182 through 190 of a light chain with the amino acids of SEQ ID NO:83, SEQ ID NO:84, SEQ ID NO:85, SEQ ID NO:86, or SEQ ID NO:87; and
(xvii) replacement of the amino acids at EU 199 through 204 of a light chain with the amino acids of SEQ ID NO:89, SEQ ID NO:90, SEQ ID NO:91, SEQ ID NO:92, SEQ ID NO:93, SEQ ID NO:94, SEQ ID NO:95, or SEQ ID NO:96;
L is a linker moiety bonded to Ab via the amide bond
to a glutamine in the replacement sequence; and
D is selected from the group consisting of a protein, a radioisotope, an assay agent, and a therapeutic agent.

### Claim 8 (depends on 7)

A conjugate according to claim 7, wherein D is a therapeutic agent.

### Claim 9 (depends on 7)

A conjugate according to claim 7, wherein D is a TLR3, TLR7, TLR9, STING, NLRP3, or RIG-I agonist.

### Claim 10 (depends on 7)

A conjugate according to claim 7, wherein L is
wherein
T is a self-immolating group;
t is 0 or 1;
AAa and each AAb are independently selected from the group consisting of alanine, β-alanine, γ-aminobutyric acid, arginine, asparagine, aspartic acid, γ-carboxyglutamic acid, citrulline, cysteine, glutamic acid, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, norleucine, norvaline, ornithine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, and valine;
p is 1, 2, 3, or 4;
q is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10; and
r is 1, 2, 3, 4, or 5.

### Claim 11 (depends on 7)

A conjugate according to claim 7, wherein the antibody comprises a modification selected from the group consisting of:
(I) replacement of the amino acids at EU 131 through 135 of a heavy chain with the amino acids of SEQ ID NO:9 or SEQ ID NO:10;
(II) replacement of the amino acids at EU 175 through 177 of a heavy chain with the amino acids of SEQ ID NO:18;
(III) replacement of the amino acids at EU 190 through 196 of a heavy chain with the amino acids of SEQ ID NO:22;
(IV) replacement of the amino acids at EU 264 through 269 of a heavy chain with the amino acids of SEQ ID NO:27 or SEQ ID NO:28;
(V) replacement of the amino acids at EU 292 through 297 of a heavy chain with the amino acids of SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:45, SEQ ID NO:100, SEQ ID NO:101, SEQ ID NO:102, or SEQ ID NO:103;
(VI) replacement of the amino acids at EU 330 through 331 of a heavy chain with the amino acids of SEQ ID NO: 51, SEQ ID NO:52 or sEQ ID NO:53;
(VII) replacement of the amino acids at EU 384 through 402 of a heavy chain with the amino acids of SEQ ID NO:57, SEQ ID NO:58, or SEQ ID NO:63;
(VIII) replacement of the amino acids at EU 414 through 419 of a heavy chain with the amino acids of SEQ ID NO:66 or SEQ ID NO:68;
(IX) replacement of the amino acids at EU 152 through 155 of a light chain with the amino acids of SEQ ID NO:73 or SEQ ID NO:75;
(X) replacement of the amino acids at EU 167 through 170 of a light chain with the amino acids of SEQ ID NO: 78 or SEQ ID NO:82; and
(XI) replacement of the amino acids at EU 199 through 204 of a light chain with the amino acids of SEQ ID NO: 92, SEQ ID NO:93 or SEQ ID NO:94.

### Claim 12

A method of making an antibody conjugate, comprising the steps of
(a) mixing a full length antibody with an amine donor compound comprising a primary amine and a moiety selected from the group consisting of a protein, a radioisotope, an assay agent, and a therapeutic agent, in the presence of a transglutaminase; the antibody having a replacement sequence selected from the group consisting of
(i) replacement of the amino acids at EU 131 through 135 of a heavy chain with the amino acids of SEQ ID NO:7, SEQ ID NO:8, and SEQ ID NO: 9 or SEQ ID NO:10;
(ii) replacement of the amino acids at EU 160 through 164 of a heavy chain with the amino acids of SEQ ID NO:11, SEQ ID NO: 12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:16, or SEQ ID NO:17;
(iii) replacement of the amino acids at EU 175 through 177 of a heavy chain with the amino acids of SEQ ID NO:18, SEQ ID NO:19, or NO:20;
(iv) replacement of the amino acids at EU 190 through 196 of a heavy chain with the amino acids of SEQ ID NO:22, SEQ ID NO:23, or SEQ ID NO:24;
(v) replacement of the amino acids at EU 264 through 269 of a heavy chain with the amino acids of SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27 or SEQ NO:28;
(vi) replacement of the amino acids at EU 280 through 284 of a heavy chain with the amino acids of SEQ ID NO:29, SEQ ID NO:30, or SEQ ID NO:31;
(vii) replacement of the amino acids at EU 292 through 297 of a heavy chain with the amino acids of SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ Id NO:36, SEQ ID NO:37, SEQ ID NO: 38, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:45, SEQ ID NO:47, SEQ ID NO:100, SEQ ID NO:101, SEQ ID NO:102, or SEQ ID NO:103;
(viii) replacement of the amino acids at EU 314 through 319 of a heavy chain with the amino acids of SEQ ID NO:48, SEQ ID NO:49 or SEQ ID NO:50;
(ix) replacement of the amino acids at EU 330 through 331 of a heavy chain with the amino acids of SEQ ID NO:51, SEQ ID NO:52, or SEQ ID NO:53;
(x) replacement of the amino acids at EU 358 through 362 of a heavy chain with the amino acids of SEQ ID NO:54 or SEQ ID NO:55;
(xi) replacement of the amino acids at EU 384 through 402 of a heavy chain with the amino acids of SEQ ID NO:56, SEQ ID NO:57, SEQ ID NO:58, SEQ ID NO:59, SEQ ID NO:60, SEQ ID NO:61, SEQ ID NO:62, SEQ ID NO:63 or SEQ ID NO:64;
(xii) replacement of the amino acids at EU 414 through 419 of a heavy chain with the amino acids of SEQ ID NO:65, SEQ ID NO:66, SEQ ID NO:67, SEQ ID NO:68, or SEQ ID NO:69;
(xiii) replacement of the amino acids at EU 122 through 126 of a light chain with the amino acids of SEQ ID NO:70, SEQ ID NO:71, or SEQ ID NO:72;
(xiv) replacement of the amino acids at EU 152 through 155 of a light chain with the amino acids of SEQ ID NO:73, SEQ ID NO:74, or SEQ ID NO:75;
(xv) replacement of the amino acids at EU 167 through 170 of a light chain with the amino acids of SEQ ID NO:76, SEQ ID NO: 77, SEQ ID NO:78, SEQ ID NO: 79, SEQ ID NO:81, or SEQ ID NO:82;
(xvi) replacement of the amino acids at EU 182 through 190 of a light chain with the amino acids of SEQ ID NO:83, SEQ ID NO:84, SEQ ID NO:85, SEQ ID NO:86, or SEQ ID NO:87; and
(xvii) replacement of the amino acids at EU 199 through 204 of a light chain with the amino acids of SEQ ID NO:89, SEQ ID NO:90, SEQ ID NO:91, SEQ ID NO:92, SEQ ID NO:93, SEQ ID NO:94, SEQ ID NO:95, or SEQ ID NO:96; and
(b) allowing the transglutaminase to catalyze the formation of an amide bond between the side chain carboxamide of a glutamine of the replacement sequence and the primary amine of the amine donor compound, thereby making the antibody conjugate.

### Claim 13 (depends on 12)

A method according to claim 12, wherein the amine donor compound has the structure
H2N-L-D
wherein L is a linker moiety and D is a protein, a radioisotope, an assay agent, or a therapeutic agent.

### Claim 14 (depends on 13)

A method according to claim 13, wherein the amine donor compound has the structure
H2N—(CH2)2-6D (I)

### Claim 15 (depends on 12)

A method according to claim 12, wherein the amine donor compound has a structure represented by formula (Ia)
wherein
D is a protein, a radioisotope, an assay agent, or a therapeutic agent;
T is a self-immolating group;
t is 0 or 1;
AAa and each AAb are independently selected from the group consisting of alanine, β-alanine, γ-aminobutyric acid, arginine, asparagine, aspartic acid, γ-carboxyglutamic acid, citrulline, cysteine, glutamic acid, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, norleucine, norvaline, ornithine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, and valine;
p is 1, 2, 3, or 4;
q is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10; and
r is 1, 2, 3, 4, or 5.

### Claim 16 (depends on 12)

A method according to claim 12, wherein the moiety is a therapeutic agent.

### Claim 17 (depends on 16)

A conjugate according to claim 16, wherein therapeutic agent is a TLR3, TLR7, TLR9, STING, NLRP3, or RIG-I agonist.

### Claim 18 (depends on 16)

A method according to claim 16, wherein the antibody has modification selected from the group consisting of:
(I) replacement of the amino acids at EU 131 through 135 of a heavy chain with the amino acids of SEQ ID NO:9 or SEQ ID NO:10;
(II) replacement of the amino acids at EU 175 through 177 of a heavy chain with the amino acids of SEQ ID NO:18;
(III) replacement of the amino acids at EU 190 through 196 of a heavy chain with the amino acids of SEQ ID NO:22;
(IV) replacement of the amino acids at EU 264 through 269 of a heavy chain with the amino acids of SEQ ID NO:27 or SEQ ID NO:28;
(V) replacement of the amino acids at EU 292 through 297 of a heavy chain with the amino acids of SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:45, SEQ ID NO:100, SEQ ID NO:101, SEQ ID NO:102, or SEQ ID NO:103;
(VI) replacement of the amino acids at EU 330 through 331 of a heavy chain with the amino acids of SEQ ID NO: 51, SEQ ID NO:52 or sEQ ID NO:53;
(VII) replacement of the amino acids at EU 384 through 402 of a heavy chain with the amino acids of SEQ ID NO:57, SEQ ID NO:58, or SEQ ID NO:63;
(VIII) replacement of the amino acids at EU 414 through 419 of a heavy chain with the amino acids of SEQ ID NO:66 or SEQ ID NO:68;
(IX) replacement of the amino acids at EU 152 through 155 of a light chain with the amino acids of SEQ ID NO:73 or SEQ ID NO:75;
(X) replacement of the amino acids at EU 167 through 170 of a light chain with the amino acids of SEQ ID NO: 78 or SEQ ID NO:82; and
(XI) replacement of the amino acids at EU 199 through 204 of a light chain with the amino acids of SEQ ID NO: 92, SEQ ID NO:93 or SEQ ID NO:94.

### Claim 19

A method of making an antibody conjugate, comprising:
(a) mixing a full length antibody with a first compound, which first compound is an amine donor compound having a primary amine and a first reactive functional group, in the presence of a transglutaminase; the antibody having a replacement sequence selected from the group consisting of
(i) replacement of the amino acids at EU 131 through 135 of a heavy chain with the amino acids of SEQ ID NO:7, SEQ ID NO:8, and SEQ ID NO: 9 or SEQ ID NO:10;
(ii) replacement of the amino acids at EU 160 through 164 of a heavy chain with the amino acids of SEQ ID NO:11, SEQ ID NO: 12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:16, or SEQ ID NO:17;
(iii) replacement of the amino acids at EU 175 through 177 of a heavy chain with the amino acids of SEQ ID NO:18, SEQ ID NO:19, or NO:20;
(iv) replacement of the amino acids at EU 190 through 196 of a heavy chain with the amino acids of SEQ ID NO:22, SEQ ID NO:23, or SEQ ID NO:24;
(v) replacement of the amino acids at EU 264 through 269 of a heavy chain with the amino acids of SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27 or SEQ NO:28;
(vi) replacement of the amino acids at EU 280 through 284 of a heavy chain with the amino acids of SEQ ID NO:29, SEQ ID NO:30, or SEQ ID NO:31;
(vii) replacement of the amino acids at EU 292 through 297 of a heavy chain with the amino acids of SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ Id NO:36, SEQ ID NO:37, SEQ ID NO: 38, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:45, SEQ ID NO:47, SEQ ID NO:100, SEQ ID NO:101, SEQ ID NO:102, or SEQ ID NO:103;
(viii) replacement of the amino acids at EU 314 through 319 of a heavy chain with the amino acids of SEQ ID NO:48, SEQ ID NO:49 or SEQ ID NO:50;
(ix) replacement of the amino acids at EU 330 through 331 of a heavy chain with the amino acids of SEQ ID NO:51, SEQ ID NO:52, or SEQ ID NO:53;
(x) replacement of the amino acids at EU 358 through 362 of a heavy chain with the amino acids of SEQ ID NO:54 or SEQ ID NO:55;
(xi) replacement of the amino acids at EU 384 through 402 of a heavy chain with the amino acids of SEQ ID NO:56, SEQ ID NO:57, SEQ ID NO:58, SEQ ID NO:59, SEQ ID NO:60, SEQ ID NO:61, SEQ ID NO:62, SEQ ID NO:63 or SEQ ID NO:64;
(xii) replacement of the amino acids at EU 414 through 419 of a heavy chain with the amino acids of SEQ ID NO:65, SEQ ID NO:66, SEQ ID NO:67, SEQ ID NO:68, or SEQ ID NO:69;
(xiii) replacement of the amino acids at EU 122 through 126 of a light chain with the amino acids of SEQ ID NO:70, SEQ ID NO:71, or SEQ ID NO:72;
(xiv) replacement of the amino acids at EU 152 through 155 of a light chain with the amino acids of SEQ ID NO:73, SEQ ID NO:74, or SEQ ID NO:75;
(xv) replacement of the amino acids at EU 167 through 170 of a light chain with the amino acids of SEQ ID NO:76, SEQ ID NO: 77, SEQ ID NO:78, SEQ ID NO: 79, SEQ ID NO:81, or SEQ ID NO:82;
(xvi) replacement of the amino acids at EU 182 through 190 of a light chain with the amino acids of SEQ ID NO:83, SEQ ID NO:84, SEQ ID NO:85, SEQ ID NO:86, or SEQ ID NO:87; and
(xvii) replacement of the amino acids at EU 199 through 204 of a light chain with the amino acids of SEQ ID NO:89, SEQ ID NO:90, SEQ ID NO:91, SEQ ID NO:92, SEQ ID NO:93, SEQ ID NO:94, SEQ ID NO:95, or SEQ ID NO:96;
(b) allowing the transglutaminase to catalyze the formation of an amide bond between the side chain carboxamide of a glutamine of the replacement sequence and the primary amine of the first compound, to make an adduct of the antibody and the first compound;
(c) contacting the adduct with a second compound having a second reactive functional group and a moiety selected from the group consisting of a protein, a radioisotope, an assay agent, and a therapeutic agent; the second reactive functional group being capable of reacting with the first reactive functional group to form a covalent bond therebetween; and
(d) allowing the first and second reactive functional groups to react and form a covalent bond therebetween, thereby making the antibody conjugate.

### Claim 20 (depends on 19)

A method according to claim 19, wherein the first compound has the structure
H2N-L′-R′
wherein L′ is a first linker moiety and R′ is a first reactive functional group and the second compound has the structure
R″-L″-D
wherein R″ is a second reactive functional group capable of reacting with R′, L″ is a second linker moiety, and D is protein, a radioisotope, an assay agent, or a therapeutic agent.

### Claim 21 (depends on 20)

A method according to claim 20, wherein R′ is selected from
and, reciprocally, R″ is selected from

### Claim 22 (depends on 20)

A method according to claim 20, wherein the first compound has a structure represented by formula (II)
H2N—(CH2)2-8—R′ (II)
and the second compound has a structure represented by formula (III)
wherein
R′ is a first reactive functional group;
R″ is a second reactive functional group capable of reacting with R′;
D is a protein, a radioisotope, an assay agent, or a therapeutic agent;
T is a self-immolating group;
t is 0 or 1;
AAa and each AAb are independently selected from the group consisting of alanine, β-alanine, γ-aminobutyric acid, arginine, asparagine, aspartic acid, γ-carboxyglutamic acid, citrulline, cysteine, glutamic acid, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, norleucine, norvaline, ornithine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, and valine;
p is 1, 2, 3, or 4;
q is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10; and
r is 1, 2, 3, 4, or 5.

### Claim 23 (depends on 22)

A method according to claim 22, wherein R′ is selected from
and, reciprocally, R″ is selected from

### Claim 24 (depends on 19)

A method according to claim 19, wherein the antibody comprises a modification selected from the group consisting of:
(I) replacement of the amino acids at EU 131 through 135 of a heavy chain with the amino acids of SEQ ID NO:9 or SEQ ID NO:10;
(II) replacement of the amino acids at EU 175 through 177 of a heavy chain with the amino acids of SEQ ID NO:18;
(III) replacement of the amino acids at EU 190 through 196 of a heavy chain with the amino acids of SEQ ID NO:22;
(IV) replacement of the amino acids at EU 264 through 269 of a heavy chain with the amino acids of SEQ ID NO:27 or SEQ ID NO:28;
(V) replacement of the amino acids at EU 292 through 297 of a heavy chain with the amino acids of SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:45, SEQ ID NO:100, SEQ ID NO:101, SEQ ID NO:102, or SEQ ID NO:103;
(VI) replacement of the amino acids at EU 330 through 331 of a heavy chain with the amino acids of SEQ ID NO: 51, SEQ ID NO:52 or sEQ ID NO:53;
(VII) replacement of the amino acids at EU 384 through 402 of a heavy chain with the amino acids of SEQ ID NO:57, SEQ ID NO:58, or SEQ ID NO:63;
(VIII) replacement of the amino acids at EU 414 through 419 of a heavy chain with the amino acids of SEQ ID NO:66 or SEQ ID NO:68;
(IX) replacement of the amino acids at EU 152 through 155 of a light chain with the amino acids of SEQ ID NO:73 or SEQ ID NO:75;
(X) replacement of the amino acids at EU 167 through 170 of a light chain with the amino acids of SEQ ID NO: 78 or SEQ ID NO:82; and
(XI) replacement of the amino acids at EU 199 through 204 of a light chain with the amino acids of SEQ ID NO: 92, SEQ ID NO:93 or SEQ ID NO:94.
